Is it possible to use anthracyclines in patients older than 70 years? Contra

Tumori

Volumn 88, Issue SUPPL. 1, 2002, Pages

  Del Mastro, Lucia ^a   Maggi, Elisa ^a   Catzeddu, Tiziana ^a   Hazini, Abdolraim ^a   Bell, Carol ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MITOXANTRONE; NAVELBINE; PREDNISONE; TAXANE DERIVATIVE; TRASTUZUMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ASTHENIA; BLADDER CANCER; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; HUMAN; INCIDENCE; INFECTION; LEUKEMIA; LYMPHOMA; MUCOSA INFLAMMATION; PHASE 3 CLINICAL TRIAL; RISK BENEFIT ANALYSIS;

EID: 0036199378     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160208800140     Document Type: Conference Paper

References (10)

1. A prospective pharmacologic evaluation of age-related toxicityof adjuvant chemotherapy in women with breast cancer
2. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer
3. Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennal measurements: Framingham heart study, 30-yeras follow-up
4. Risk factors for doxorubicin-induced congestive heart failure
5. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer
6. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: The M.D. Anderson experience
7. Gemcitabine and Cisplatin versus methotrexate, vinblastine, doxorubicin, and cislatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study
8. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy
9. CHOP is the standard regimen in patients > 70 years of age with intermediate-grade and high-grade non-Hodgkin lymphoma: Results of a randomized study of the european Organization for Research and Treatment of Cancer lymphoma cooperative study group
10. Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high grade lymphoma: Results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO